Skip to content

Boosting research and development into polycystic kidney disease

27 June 2023

Polycystic kidney disease (PKD) is the world’s most common inherited kidney disease with significant unmet needs and limited treatment options. Together with the PKD Charity, we’re committed to boosting research and development into PKD. We are forming a new PKD Research Consortium that will bring together scientific and clinical experts to accelerate treatment development and transform the lives of people living with PKD.  

Our vision for the PKD Research Consortium 

Our aim for the consortium is to combine experimental modelling, genetic and clinical data to generate insights and identify ways to treat the disease. The consortium will drive collaboration in this area and find new targets for drug development, or repurposing, to improve outcomes for patients.  

Consultancy support needed

We’re looking for a consultancy who can undertake a scoping study to help us establish the PKD Research Consortium.  

The proposed scoping study will be required to include: 

  • governance guidance and support 
  • information collection from stakeholders and intended academic centres 
  • identifying the barriers and opportunities for clinical trials.  

Find out more 

For more information about the PKD Research Consortium, and the scoping study requirements, download our PKD Consortium Consultancy Briefing document. Alternatively, if you have any questions or would like to discuss it further, contact Alan Greenberg, PKD Charity chair of trustees.  

If your organisation can help support us, please send an expressions of interest to by 31 July 2023.

Get our e-newsletter

Stay up to date with our kidney research news, events and ways to get involved.

Scroll To Top